Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA Monitoring to Predict the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

NCT06589388 is registered in ClinicalTrials.gov with Gene Solutions as lead sponsor.

NCT NCT06589388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06589388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA Monitoring to Predict the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
Lead sponsor
Gene Solutions
Phase
Observational
Overall status
Recruiting
Start date
May 21, 2024
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer, rectal cancer stage ii, rectal cancer stage iii